E
Edward Campanaro
Researcher at Cubist Pharmaceuticals
Publications - 5
Citations - 659
Edward Campanaro is an academic researcher from Cubist Pharmaceuticals. The author has contributed to research in topics: Internal medicine & Randomized controlled trial. The author has an hindex of 1, co-authored 1 publications receiving 629 citations.
Papers
More filters
Journal ArticleDOI
The Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-Structure Infections
Robert D. Arbeit,Dennis G. Maki,Francis P. Tally,Edward Campanaro,Barry I. Eisenstein,Investigators +5 more
TL;DR: The safety and efficacy of daptomycin were comparable with conventional therapy, and the frequency and distribution of adverse events were similar among both treatment groups.
Journal ArticleDOI
Safety, Pharmacokinetics, Serum Neutralizing Titers, and Immunogenicity of Adintrevimab, a Monoclonal Antibody Targeting SARS-CoV-2: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Dose-escalation Study in Healthy Adults
Pete Schmidt,Jean Gong,Kristin Narayan,Deepali Gupta,Frank A. Engler,Yong Li,Amanda Copans,Edward Campanaro +7 more
TL;DR: Adintrevimab is a fully human immunoglobulin G1 extended half-life monoclonal antibody that was developed to have broad neutralization against SARS-CoV, SARS CoV-2, and other SARSlike CoVs with pandemic potential as discussed by the authors .
Journal ArticleDOI
226. Higher Doses of Adintrevimab, an Extended Half-Life Monoclonal Antibody, for the Treatment and Prevention of COVID-19: Preliminary Results from a Phase 1 Single Ascending-Dose Study
Xia Pu,Jean Gong,Edward Campanaro,Kristin Narayan,Deepali Gupta,Frank A. Engler,Amanda Copans,Pete Schmidt +7 more
TL;DR: In this paper, the authors report higher doses being evaluated in a healthy volunteer study given that emerging SARS-CoV-2 variants may have varying susceptibilities to adintrevimab.
Journal ArticleDOI
Efficacy and Safety of Adintrevimab (ADG20) for the Treatment of High-Risk Ambulatory Patients With Mild or Moderate Coronavirus Disease 2019: Results From a Phase 2/3, Randomized, Placebo-Controlled Trial (STAMP) Conducted During Delta Predominance and Early Emergence of Omicron
Michael G. Ison,Myra Popejoy,Nikolay Evgeniev,Maria Tzekova,K. A. Mahoney,Natalia Betancourt,Yong Li,Deepali Gupta,Kristin Narayan,Ellie Hershberger,Lynn E. Connolly,Ilker Yalcin,Anita Das,John W. Genge,M. Smith,Edward Campanaro,Pamela Hawn,Pete Schmidt,K. Palaveev,L. Pekova,N. Nikolaev,M. Kornmann,Olaf Schmidt,Garyfalia Poulakou,Charalampos Milionis,D. Kofteridis,Meletios A. Dimopoulos,Anastasia Kotanidou,Sotirios Tsiodras,Grzegorz Kania,Tomasz Zaj,Anca Streinu-Cercel,Larisha Pillay-Ramaya,Mohamed Mookadam,Lerato Mohapi,Yacoob Vahed,C. Holmgren,Martha Mekebeb-Reuter,William Brumskine,Douwe Marcus de Jong,Natasha Joseph,Kirsten McHarry,Shahid Wadvalla,Olena Kobrynska,Igor Kireyev,Kyrylo Lebed,Olga Barna,Olga Gyrina,Viktoriya Rodionova +48 more
TL;DR: In this article , the authors report results from STAMP, a phase 2/3, multicenter, double-blind, randomized, placebo-controlled trial of adintrevimab, an extended half-life monoclonal antibody, for treatment of high-risk ambulatory patients with mild to moderate COVID-19.
Journal ArticleDOI
Prevention of COVID-19 Following a Single Intramuscular Administration of Adintrevimab: Results From a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial (EVADE)
Michael G. Ison,M. L. Dobryanska,Ann Phelan,Yong Li,Deepali Gupta,Kristin Narayan,Ellie Hershberger,Lynn E. Connolly,Ilker Yalcin,Edward Campanaro,Pamela Hawn,Pete Schmidt +11 more
TL;DR: The EVADE trial as mentioned in this paper was a phase 2/3 multicenter, double-blind, randomized, placebo-controlled trial of adintrevimab, an extended-half-life monoclonal antibody, for pre-exposure prophylaxis (PrEP) of symptomatic COVID-19.